These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19767319)

  • 1. Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women.
    Dryer PD; Limketkai BN; Martin CM; Ma G; Sherman KE; Taylor LE; Mayer KH; Jamieson DJ; Blackard JT
    J Antimicrob Chemother; 2009 Nov; 64(5):945-8. PubMed ID: 19767319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
    Paolucci S; Fiorina L; Mariani B; Gulminetti R; Novati S; Barbarini G; Bruno R; Baldanti F
    Virol J; 2013 Dec; 10():355. PubMed ID: 24341898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.
    Alves R; Queiroz AT; Pessoa MG; da Silva EF; Mazo DF; Carrilho FJ; Carvalho-Filho RJ; de Carvalho IM
    J Viral Hepat; 2013 Jun; 20(6):414-21. PubMed ID: 23647958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database.
    Kliemann DA; Tovo CV; da Veiga AB; de Mattos AA; Wood C
    World J Gastroenterol; 2016 Oct; 22(40):8910-8917. PubMed ID: 27833382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
    Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
    Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.
    Costantino A; Spada E; Equestre M; Bruni R; Tritarelli E; Coppola N; Sagnelli C; Sagnelli E; Ciccaglione AR
    Virol J; 2015 Nov; 12():186. PubMed ID: 26577836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of drug-resistance-associated mutations and genetic barriers in hepatitis C virus NS5B sequences in China.
    Nie B; Guo Y; Zhang K; Liu J; Yun S
    Arch Virol; 2020 Sep; 165(9):2013-2020. PubMed ID: 32601956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor.
    Voitenleitner C; Crosby R; Walker J; Remlinger K; Vamathevan J; Wang A; You S; Johnson J; Woldu E; Van Horn S; Horton J; Creech K; Shotwell JB; Hong Z; Hamatake R
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5216-24. PubMed ID: 23939896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No detection of the NS5B S282T mutation in treatment-naïve genotype 1 HCV/HIV-1 coinfected patients using deep sequencing.
    Franco S; Casadellà M; Noguera-Julian M; Clotet B; Tural C; Paredes R; Martinez MA
    J Clin Virol; 2013 Dec; 58(4):726-9. PubMed ID: 24140031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.
    Howe AY; Cheng H; Johann S; Mullen S; Chunduru SK; Young DC; Bard J; Chopra R; Krishnamurthy G; Mansour T; O'Connell J
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3327-38. PubMed ID: 18559648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
    Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
    Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amino Acid Mutations in NS5B Protein among Treatment-naive Genotype 3A Infected Patients.
    Gul A; Ali I; Gul N; Ahmed J
    J Coll Physicians Surg Pak; 2019 Dec; 29(12):1149-1152. PubMed ID: 31839085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C.
    Ahmed HR; Waly NGFM; Abd El-Baky RM; Yahia R; Hetta HF; Elsayed AM; Ibrahem RA
    PLoS One; 2021; 16(4):e0249770. PubMed ID: 33857212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of resistant associated variants (RAVs) in the naïve HCV patient candidate for direct acting antiviral (DAA) therapy.
    Karbalaie Niya MH; Salman-Tabar S; Bokharaei-Salim F; Behmanesh M; Keyvani H
    Microb Pathog; 2017 Apr; 105():166-170. PubMed ID: 28161357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates.
    Jaspe RC; Sulbarán YF; Sulbarán MZ; Loureiro CL; Rangel HR; Pujol FH
    Virol J; 2012 Sep; 9():214. PubMed ID: 22995142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa.
    Prabdial-Sing N; Blackard JT; Puren AJ; Mahomed A; Abuelhassan W; Mahlangu J; Vermeulen M; Bowyer SM
    Antiviral Res; 2016 Mar; 127():90-8. PubMed ID: 26704023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.
    Kati W; Koev G; Irvin M; Beyer J; Liu Y; Krishnan P; Reisch T; Mondal R; Wagner R; Molla A; Maring C; Collins C
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1505-11. PubMed ID: 25534735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay.
    Ludmerer SW; Graham DJ; Boots E; Murray EM; Simcoe A; Markel EJ; Grobler JA; Flores OA; Olsen DB; Hazuda DJ; LaFemina RL
    Antimicrob Agents Chemother; 2005 May; 49(5):2059-69. PubMed ID: 15855532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients.
    Le Pogam S; Seshaadri A; Kosaka A; Chiu S; Kang H; Hu S; Rajyaguru S; Symons J; Cammack N; Nájera I
    J Antimicrob Chemother; 2008 Jun; 61(6):1205-16. PubMed ID: 18343801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Naturally occurring NS5B variants resistant to non-nucleoside or nucleoside polymerase inhibitors among treatment-naïve hepatitis C patients in south China].
    Li Z; Liu Y; Cai Q; Shao X; Yan Y; Zhao Z
    Zhonghua Gan Zang Bing Za Zhi; 2015 Sep; 23(9):653-7. PubMed ID: 26524357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.